KPV

KPV is described as the C-terminal tripeptide segment of α-melanocyte-stimulating hormone (α-MSH) that retains anti-inflammatory activity while lacking the parent hormone’s melanotropic (pigmentation) effects. In the protocol, KPV’s primary mechanism is immune-signaling modulation: preclinical studies cited describe reductions in pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β across models of colitis, inflammatory bowel disease, and systemic inflammation. The page attributes these effects to inhibition of NF-κB signaling and broader modulation of inflammatory mediator release. While multiple routes are discussed, the protocol frames subcutaneous administration as providing consistent systemic exposure and rapid absorption for daily-use research schedules. The overall ‘how it works’ narrative is inflammation dampening through cytokine downregulation and NF-κB pathway inhibition, with an emphasis on tolerability and the absence of pigmentation-related activity that would be expected from full α-MSH.